Thymopentin for allergy symptoms — EP0235904A2
Patent disclosure · 1987
- What the patent describes
- 30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
- Reported evidence
- In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.
Mean weekly symptom count, IV arm · 9.20 versus 19.22 with placebo (p=0.0145).
Reported patent results
Reported findings
In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.
30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
Population or model 30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean weekly symptom count, IV arm | 9.20 versus 19.22 with placebo (p=0.0145). | |
| Mean weekly symptom count, subcutaneous arm | 12.84 versus 19.22 with placebo (p=0.1394). |
Average weekly symptom counts from Table I
| Group (10 assigned each) | Mild | Severe | Total | Total p vs placebo |
|---|---|---|---|---|
| 50 mg subcutaneous | 10.20 | 2.64 | 12.84 | 0.1394 |
| 100 mg intravenous | 7.43 | 1.77 | 9.20 | 0.0145 |
| Placebo | 13.90 | 5.32 | 19.22 | — |
The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.
Source for these results ↗ · Reviewed 2026-11-14
Patent claims and provenance
Use. Claims use of thymopentin or a salt for allergy symptoms. The measured human example concerns ragweed allergic rhinitis.
The European and US texts describe the same 30-person trial. A 1986 conference abstract is cited in the family and may describe the same cohort.
- Publication
- EP0235904A2 ↗ · 1987-09-09
- Earliest priority / filing
- 1986-01-24 / 1987-01-23
- Original applicant / assignee
- Ortho Pharmaceutical Corp
- Indexed status
- Withdrawn · checked 2026-11-14
- Patent family
- 25236742 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Treatment of allergy with thymopentin
Inventors: Gideon Goldstein.
Study limitations and source details
Study limitations
- The European and US texts describe the same 30-person trial. A 1986 conference abstract is cited in the family and may describe the same cohort.
- The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Related publications may describe some of the same participants or experiments.
Source details
Patent publication · Original patent text and indexed metadata
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sources checked
Citation
Published
Gideon Goldstein. Thymopentin for allergy symptoms — EP0235904A2 EP0235904A2 · patent family 25236742